Skip to main content
. 2016 Mar;101(3):371–381. doi: 10.3324/haematol.2015.134155

Figure 2.

Figure 2.

Modest accumulation of aberrant CD56−CD16+ NK cells in patients undergoing HCMV reactivation after αβ+ T/B cell-depleted transplant as compared to patients receiving UCBT or purified CD34+ cells. PBNK cells from the various patients were analyzed for the expression of CD56 and CD16 at 1, 3, 6 and 12 months after HSCT. In (A), the percentages of CD56−CD16+ NK cells in patients experiencing HCMV (empty circles, n=13) or not (filled black squares, n=14) after transplantation are reported at the different time points. 95% CI for the mean and statistical significance are indicated (*P<0.05; ** P<0.01; *** P<0.001). In (B), the percentages of CD56−CD16+ NK cells measured in αβ+ T/B cell-depleted haplo-HSCT (n=13) patients are compared to those measured in two different groups of pediatric patients reactivating HCMV after transplantation who received either cord blood transplantation (UCBT) (n=5) or positively selected CD34+ HSC (CD34+ haplo-HSCT) (n=5). The values reported correspond to 6 months after HSCT for all patients. 95% CI for the mean and statistical significance are indicated.